Efficacy and safety of continuous low-irradiance photodynamic therapy in the treatment of chest wall progression of breast cancer

Morrison, Sara A.; Hill, Samuel L.; Rogers, Gary S.; Graham, Roger A.

doi:10.1016/j.jss.2014.06.030

Cited by 43 publications

(27 citation statements)

References 12 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Recent publications by other groups further support those findings [31,43]. Additionally, clinical observations report the regression of lesions outside the treatment field after PDT-treatment as well, thus indicating the generation of systemic immunity in human patients [44,45,46]. …”

Section: Pdt and Adaptive Immunitysupporting

confidence: 54%

Boosting Tumor-Specific Immunity Using PDT

Maeding

Verwanger

Krammer

2016

Cancers

View full text Add to dashboard Cite

Photodynamic therapy (PDT) is a cancer treatment with a long-standing history. It employs the application of nontoxic components, namely a light-sensitive photosensitizer and visible light, to generate reactive oxygen species (ROS). These ROS lead to tumor cell destruction, which is accompanied by the induction of an acute inflammatory response. This inflammatory process sends a danger signal to the innate immune system, which results in activation of specific cell types and release of additional inflammatory mediators. Activation of the innate immune response is necessary for subsequent induction of the adaptive arm of the immune system. This includes the priming of tumor-specific cytotoxic T lymphocytes (CTL) that have the capability to directly recognize and kill cells which display an altered self. The past decades have brought increasing appreciation for the importance of the generation of an adaptive immune response for long-term tumor control and induction of immune memory to combat recurrent disease. This has led to considerable effort to elucidate the immune effects PDT treatment elicits. In this review we deal with the progress which has been made during the past 20 years in uncovering the role of PDT in the induction of the tumor-specific immune response, with special emphasis on adaptive immunity.

show abstract

Section: Pdt and Adaptive Immunitysupporting

confidence: 54%

Boosting Tumor-Specific Immunity Using PDT

Maeding

Verwanger

Krammer

2016

Cancers

View full text Add to dashboard Cite

show abstract

“…Resultant cell debris from tumor cell death at the site of targeted therapy attracts macrophages, neutrophils, and dendritic cells, allowing tumor cell antigens to be exposed to the immune system. This process subsequently results in clonal expansion of tumor‐specific lymphocytes which can allow for long‐term targeted response . In murine models, it has been shown that healthy immune function is necessary for curative PDT outcomes .…”

Section: Mechanism Of Actionmentioning

confidence: 99%

Photodynamic therapy for solid tumors: A review of the literature

Yanovsky

Bartenstein

Rogers

et al. 2019

Photoderm Photoimm Photomed

Self Cite

170

102

View full text Add to dashboard Cite

Photodynamic therapy (PDT) utilizes a sensitizer agent and light to produce selective cell death. Dermatologists are familiar with PDT for the treatment of actinic keratoses and early nonmelanoma skin cancers, and recent studies have elucidated that PDT has resulted in improved morbidity and secondary outcomes for the treatment of various cancerous and precancerous solid tumors. Light source and dosimetry may be modified to selectively target tissue, and novel techniques such as fractionation, metronomic pulsation, continuous light delivery, and chemophototherapy are under investigation for further optimization of therapy. This article aims to review the expanding indications for PDT and demonstrate the potential of this modality to decrease morbidity and increase quality of life for patients. To illustrate these new indications, we provide a focused review of the latest literature on PDT for dermatologic and other solid tumors including gastrointestinal, peritoneal, lung, genitourinary, brain, breast, and head and neck. Data on efficacy, survival, and side effects vary across tumor types but support PDT for the treatment of numerous solid tumors. With new advances in PDT, indications for this therapeutic modality may expand.

show abstract

“…The selectivity of photosensitizer for diseased tissue, as well as the ability to target the light directly to diseased areas, has prompted interest in studying PDT as an organ-preserving treatment for premalignant and malignant conditions. Clinical reports of PDT in the treatment of malignancies include head and neck cancers [1], lung cancer [2,3], mesothelioma [4], esophageal [5], brain [6], breast [7,8], bladder [9,10], and prostate cancers [11]. …”

Section: Introductionmentioning

confidence: 99%

Toxicities and early outcomes in a phase 1 trial of photodynamic therapy for premalignant and early stage head and neck tumors

et al. 2016

View full text Add to dashboard Cite

SUMMARY Objectives Management of early superficial lesions in the head and neck remains complex. We performed a phase 1 trial for high-grade premalignant and early superficial lesions of the head and neck using photodynamic therapy (PDT) with Levulan (ALA). Materials and methods Thirty-five subjects with high grade dysplasia, carcinoma in situ, or microinvasive (≤1.5 mm depth) squamous cell carcinoma were enrolled. Cohorts of 3–6 patients were given escalating intraoperative light doses of 50–200 J/cm2 4–6 h after oral administration of 60 mg/kg ALA. Light at 629–635 nm was delivered in a continuous (unfractionated) or fractionated (two-part) schema. Results PDT was delivered to 30/35 subjects, with 29 evaluable. There was one death possibly due to the treatment. The regimen was otherwise tolerable, with a 52% rate of grade 3 mucositis which healed within several weeks. Other toxicities were generally grade 1 or 2, including odynophagia (one grade 4), voice alteration (one grade 3), and photosensitivity reactions. One patient developed grade 5 sepsis. With a median follow-up of 42 months, 10 patients (34%) developed local recurrence; 4 of these received 50 J/cm2 and two each received 100, 150, and 200 J/cm2. Ten (34%) patients developed recurrence adjacent to the treated field. There was a 69% complete response rate at 3 months. Conclusions ALA-PDT is well tolerated. Maximum Tolerated Dose appears to be higher than the highest dose used in this study. Longer followup is required to analyze effect of light dose on local recurrence. High marginal recurrence rates suggest use of larger treatment fields.

show abstract

Efficacy and safety of continuous low-irradiance photodynamic therapy in the treatment of chest wall progression of breast cancer

Cited by 43 publications

References 12 publications

Boosting Tumor-Specific Immunity Using PDT

Boosting Tumor-Specific Immunity Using PDT

Photodynamic therapy for solid tumors: A review of the literature

Toxicities and early outcomes in a phase 1 trial of photodynamic therapy for premalignant and early stage head and neck tumors

Contact Info

Product

Resources

About